The biotechnology company has closed the funding round it started in December 2013.

Juno Therapeutics, which is developing novel immunotherapies for cancer, has closed its series A with $176m, having opened it with $120m this past December – already then one of the largest series A rounds ever. The round was closed through expansions from founding investors, as well as an investment from Bezos Expeditions, the personal investment…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.